William B. Cyr

CEO Cyr sells 46,814 shares for $2,389,428.87 via 5 transactions on 2026-05-22 under 10b5-1 plan

William B. Cyr, CEO of Freshpet, executed 5 separate sales totaling 46,814 shares for $2,389,428.87 at an average price of $51.04 on 2026-05-22, reducing his non-derivative holdings from 102,935 shares to 56,121 shares. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, making it scheduled rather than discretionary. While the current price of $52.33 is -39.4% from the 52-week high and down -20.0% over 30 days, the insider's cross-ticker track record shows 19 prior sells with an average 90-day return of +3.2%, though his prior five trades at FRPT (all on 2026-05-18) averaged positive subsequent returns. Notably, the CEO retains derivative holdings representing option positions across four ownership vehicles, indicating his long-term economic exposure to the company remains significant despite the non-derivative share reduction.

CEO Cyr sells 47,582 shares for $2.3M at blended average $47.88 via pre-arranged 10b5-1 plan

William B. Cyr, Chief Executive Officer, executed 4 separate sales totaling 47,582 shares for $2,278,259.44 on 2026-05-20 under a 10b5-1 trading plan adopted on 2025-11-05. This transaction reduced his holdings by 48.9%, from 97,315 shares to 49,733 shares post-transaction. While the sale occurred at a blended average price of $47.88, the stock now trades at $51.58 current price, and the company shows solid fundamentals (P/E of 12.64, 13.0% annual revenue growth, and $48.5M net income on $297.6M quarterly revenue). His prior trades at FRPT (5 sales on 2026-05-18) all closed with positive returns: 90-day returns ranged from flat to 5.9%. Because this sale was scheduled under a pre-arranged 10b5-1 plan, it represents a committed trade sequence unrelated to discretionary timing judgment.

CEO Cyr sells 94,364 shares ($4.6M) via scheduled 10b5-1 plan; stock down -31.8% in 30 days, -47.2% from 52-week high

William B. Cyr, CEO of Freshpet, executed 13 separate sales totaling 94,364 shares for $4,638,364.50 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-05, reducing his holdings by 68.5% from 137,841 to 43,477 shares. The sales occurred across two trading dates (2026-05-15 and 2026-05-18) at a blended average price of $49.15, while the current stock price stands at $47.39—a 31.8% decline over the past 30 days and 47.2% below the 52-week high of $89.80. The company's fundamentals remain solid with FY revenue growth of 13.0%, a P/E of 11.62, and latest-quarter net income of $48,508,000.00, but the timing of this large liquidation by the chief executive against a backdrop of significant recent stock deterioration warrants investor attention to whether near-term operational headwinds prompted the plan's adoption or whether price weakness emerged after plan scheduling.

Director Cyr William B. bought 6,000 shares of VITL at $8.52 on 2026-05-14; stock now $8.28, down -84.4% from 52-week high.

Director Cyr William B. purchased 6,000 shares at $8.52 on 2026-05-14, increasing his holdings by 77.0% to 13,794 shares total. The stock has declined significantly: current price $8.28 is -84.4% from the 52-week high of $53.12, and down -70.7% over the past 90 days. His prior buy at this ticker on 2026-03-02 showed a 90-day return of -58.2%, and across his cross-ticker track record, his 1 prior buy had an average 90-day return of -58.2% with a 0.00% win rate over 90 days. The company posted net income of $-1,522,000.00 for the latest quarter despite revenue growth of +25.3% year-over-year, and a cluster of 3 other insiders also bought within the past 14 days.

CEO Cyr sells 46,818 shares for $2,293,056.36 via scheduled 10b5-1 plan; stock down 28.3% in 30 days.

William B. Cyr executed 11 separate sales totaling 46,818 shares for $2,293,056.36 on 2026-05-13 under a pre-arranged 10b5-1 trading plan adopted 2025-11-05, reducing his holding from 77,646 shares to 30,828 shares. The stock has declined 28.3% over the past 30 days and is down 45.0% from its 52-week high of $89.80, trading at $49.35 versus transaction prices ranging from $10.23 to $51.07. Because this sale is part of a scheduled 10b5-1 plan, execution timing was predetermined and not discretionary. The insider's cross-ticker track record shows 1 prior buy with an average 90-day return of -58.2% and a 0.00% win rate, providing limited historical context for assessing this equity sales decision.

CEO Cyr exercises $859K in stock while selling $2.36M as stock trades well below 52-week highs.

CEO William B. Cyr exercised stock options worth $859K and immediately sold approximately half of his total holdings for $2.36M on the same day, netting a gain of roughly $37,500 shares while taking profits on the larger portion at prices well above his exercise price. The stock is trading roughly 46% below its 52-week high and has declined significantly over the past quarter, creating a disconnect: while Cyr expanded his net position, the scale of simultaneous selling suggests liquidity management rather than conviction. Freshpet remains profitable with solid revenue growth, but the CEO's hedging behavior—exercising equity compensation while aggressively diversifying exposure—suggests he is managing personal capital risk despite the company's operational strength. This is Cyr's first round of open-market sales at Freshpet in three years, making the volume and timing noteworthy.

Director Cyr William B. bought 4,750 shares of VITL at $20.70, tripling holdings to 7.8K shares amid -61.8% decline from 52-week high.

Director William B. Cyr purchased 4,750 shares at $20.70 on 2026-03-02, increasing his holdings by 156.0% from 3,044 to 7.8K shares. The purchase occurred at a price significantly depressed relative to the 52-week range ($20.01–$52.41), with the stock down 61.8% from its 52-week high and 27.1% lower over the past 30 days. Vital Farms maintains solid fundamentals with $198.9M quarterly revenue, +25.3% annual growth, $16.4M net income, and a 11.91 P/E ratio, suggesting the depressed valuation does not reflect operational deterioration. The substantial accumulation by a director during a period of significant price weakness merits investor attention regarding whether board-level confidence in long-term value has been activated.